Skip to main content
 
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet 

Investors & Media

Corporate Profile

Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its... More

Recent NewsMore
04/17/18
Seres Therapeutics Presents New Preclinical Data Supporting the Development of Microbiome Therapeutics for Immuno-Oncology at the 2018 American Association for Cancer Research Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 17, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that new preclinical data supporting the development of microbiome therapeutics for immuno-oncology (leveraging gut microbiota to impact tumor immunotherapy)1 will be presented today by Sceneay et al in the late breaking poster session at the 2018 American Association for Cancer Research Annual Meeting (AACR) in Chicago. The data presen... 
03/09/18
Seres Therapeutics to Present at Two Upcoming March Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 9, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced it will present at each of the following upcoming healthcare conferences: The 38th Annual Cowen & Co. Health Care Conference: a corporate overview will be presented on Wednesday, March 14 at 10:40 a.m. ET in Boston, MA. Oppenheimer's 28th Annual Healthcare Conference: a corporate overview wil... 
03/08/18
Seres Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates
- Positive SER-287 Phase 1b clinical and microbiome results support further development; Company plans to initiate next clinical trial in mid-2018 - - Preliminary Phase 1b study data obtained for SER-262, the first ever rationally-designed fermented microbiome therapeutic candidate evaluated in humans– - Collaboration with MD Anderson and Parker Institute intends to initiate clinical study in 2018 to evaluate microbiome therapeutic... 
EventsMore
Download DocumentationCorporate Presentation

There are currently no upcoming events scheduled.
Stock Quote
NASDAQ:MCRB
$7.61
 - 0.12 (1.55%)
04/23/18 4:00 p.m. ET
Refresh quote
E-mail Alerts
Sign up to receive e-mail alerts whenever Seres Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Request Information

Obtain investor relations information by contacting us.

More
Data provided by Nasdaq. Minimum 15 minutes delayed.